162 related articles for article (PubMed ID: 38407866)
1. Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD.
Bais T; Geertsema P; Knol MGE; van Gastel MDA; de Haas RJ; Meijer E; Gansevoort RT;
Clin J Am Soc Nephrol; 2024 May; 19(5):591-601. PubMed ID: 38407866
[TBL] [Abstract][Full Text] [Related]
2. Predicting Future Renal Function Decline in Patients with Autosomal Dominant Polycystic Kidney Disease Using Mayo Clinic Classification.
Borrego Utiel FJ; Esteban de la Rosa RJ; Merino García E; Medina Benítez A; Polo Moyano A; Moriana Domínguez C; Morales García AI; Bravo Soto JA
Am J Nephrol; 2021; 52(8):630-641. PubMed ID: 34518464
[TBL] [Abstract][Full Text] [Related]
3. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
Bae KT; Shi T; Tao C; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE; Srivastava A; Irazabal MV; Abebe KZ; Harris PC; Landsittel DP;
J Am Soc Nephrol; 2020 Jul; 31(7):1640-1651. PubMed ID: 32487558
[TBL] [Abstract][Full Text] [Related]
4. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
[TBL] [Abstract][Full Text] [Related]
5. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
[TBL] [Abstract][Full Text] [Related]
6. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
Lavu S; Vaughan LE; Senum SR; Kline TL; Chapman AB; Perrone RD; Mrug M; Braun WE; Steinman TI; Rahbari-Oskoui FF; Brosnahan GM; Bae KT; Landsittel D; Chebib FT; Yu AS; Torres VE; ; Harris PC
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634120
[TBL] [Abstract][Full Text] [Related]
7. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
[TBL] [Abstract][Full Text] [Related]
8. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.
Irazabal MV; Rangel LJ; Bergstralh EJ; Osborn SL; Harmon AJ; Sundsbak JL; Bae KT; Chapman AB; Grantham JJ; Mrug M; Hogan MC; El-Zoghby ZM; Harris PC; Erickson BJ; King BF; Torres VE;
J Am Soc Nephrol; 2015 Jan; 26(1):160-72. PubMed ID: 24904092
[TBL] [Abstract][Full Text] [Related]
9. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
[TBL] [Abstract][Full Text] [Related]
10. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
[TBL] [Abstract][Full Text] [Related]
11. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
[TBL] [Abstract][Full Text] [Related]
12. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
[TBL] [Abstract][Full Text] [Related]
13. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
Heida JE; Gansevoort RT; Messchendorp AL; Meijer E; Casteleijn NF; Boertien WE; Zittema D;
Clin J Am Soc Nephrol; 2021 Feb; 16(2):204-212. PubMed ID: 33504546
[TBL] [Abstract][Full Text] [Related]
14. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
[TBL] [Abstract][Full Text] [Related]
15. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
[TBL] [Abstract][Full Text] [Related]
17. Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.
Girardat-Rotar L; Braun J; Puhan MA; Abraham AG; Serra AL
BMC Nephrol; 2017 Jul; 18(1):241. PubMed ID: 28716055
[TBL] [Abstract][Full Text] [Related]
18. Combining genotype with height-adjusted kidney length predicts rapid progression of ADPKD.
Chen EWC; Chong J; Valluru MK; Durkie M; Simms RJ; Harris PC; Ong ACM
Nephrol Dial Transplant; 2024 May; 39(6):956-966. PubMed ID: 38224954
[TBL] [Abstract][Full Text] [Related]
19. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
[TBL] [Abstract][Full Text] [Related]
20. Automated prognosis of renal function decline in ADPKD patients using deep learning.
Raj A; Tollens F; Caroli A; Nörenberg D; Zöllner FG
Z Med Phys; 2024 May; 34(2):330-342. PubMed ID: 37612178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
